Please help us spread the word.
We are hiring postdoctoral fellows in Clinical Epidemiology and Pharmacoepidemiology.
Details and application via Indeed.
Please help us spread the word.
We are hiring postdoctoral fellows in Clinical Epidemiology and Pharmacoepidemiology.
Details and application via Indeed.
Honored to speak at Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing forward!!!
29.04.2025 21:58 — 👍 152 🔁 18 💬 11 📌 2
This story gets wilder. One of the researchers who is helping design this new generation of addictive foods is on GLP-1!!!
Wild but true.
buff.ly/40QHDnk
For decades, the junk food industry has deliberately engineered foods to be addictive. GLP-1 drugs have helped people break free from this cycle. The industry is now searching for ways to undo the effects of these meds, aiming to design foods that remain addictive for those on GLP1. buff.ly/40QHDnk
10.02.2025 20:56 — 👍 128 🔁 58 💬 7 📌 2
GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction.
03.02.2025 17:43 — 👍 49 🔁 12 💬 1 📌 0
New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics.
Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues.
www.nordforsk.org/2025/knowled...
Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés
My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris. @theconversation.com @france.theconversation.com
theconversation.com/alzheimer-ad...
I talked to Dani Blum from @nytimes.com about the potential role of GLP-1 drugs (Ozepmic and similar drugs) on Alzheimer’s disease.
They seem promising, but more data is needed.
www.nytimes.com/2025/01/31/w...
@us.theconversation.com piece here:
theconversation.com/ozempic-and-...
Substack here:
ziyadalaly.substack.com/p/unpacking-...
🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions.
www.nature.com/articles/s41...
📄 Free access to the full study: rdcu.be/d6VYU
New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (e.g. Ozempic and similar weight loss drugs) across 175 health conditions.
Please share and download before it goes back behind paywall.
Happy to do it. Reach out by email please (Gmail).
20.01.2025 20:57 — 👍 1 🔁 0 💬 1 📌 0
Thanks to Kristina Sauerwein for the press release and Abeeha Shamshad and Jessica Church for media outreach
Thanks to our reviewers, editors and all those supported us.
Link to press release medicine.washu.edu/news/study-i...
A lot of people who would benefit from GLP1 are not able to access them due to cost. Access issues to these meds should be solved.
www.nature.com/articles/s41...
While I am enthusiastic about the potential for GLP1 meds in helping address the obesity epidemic, prevention must remain the foundation of our approach to health and well-being.
www.nature.com/articles/s41...
The beneficial effects on many conditions (e.g. Alzheimer’s) may implicate GLP1 in their mechanisms – and open new therapeutic avenues (e.g. GLP1 could play a role in mechanism of Alzheimer’s and may be effective treatments)
www.nature.com/articles/s41...
c. I am struck by the consistent effect on addiction disorders – it elevates the likelihood that obesity itself is a form of addiction to food (in excess of caloric need) and that addressing it effectively requires drugs that work on that pathway.
www.nature.com/articles/s41...
Some thoughts:
a. Obesity is a chronic disease – it is not lack of willpower
b. Treating obesity itself – likely has many downstream benefits beyond just weight loss
www.nature.com/articles/s41...
GLP1 increased risks of gastrointestinal disorders, hypotension, syncope, arthritic disorders,
nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.
GLP1 reduced risks of substance use and psychotic disorders,
seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious
illnesses and several respiratory conditions.
The results show that GLP1 have a wide-ranging beneficial profile but are not without risks.
GLP1 meds were associated with reduced risk of 42 (24%) outcomes and increased risk of 19 outcomes (11%).
www.nature.com/articles/s41...
We included several controls - people on sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors and people on usual care who did not start GLP1
We followed study participants for 3.7 years
www.nature.com/articles/s41...
So, we decided to do the comprehensive study!
We did a discovery analysis which comprehensively examined 175 possible health outcomes (leaving no stone unturned) in 215,970 people on GLP1 and more than 2 million individuals not on GLP1.
www.nature.com/articles/s41...
Why we did this study?
We saw that GLP1 use has substantially increased, and reports started to emerge about off-target beneficial effects. But realized that no one had comprehensively investigated effectiveness and risks of GLP-1 across all possible health outcomes
www.nature.com/articles/s41...
The latest from my team in Nature Medicine.
We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound).
By @Biostayan, Taeyoung Choi and me
A 🧵
www.nature.com/articles/s41...
My first post has to be about #LongCOVID
🔹 400 million individuals affected worldwide
🔹 $1 trillion in annual economic costs
🔹 Countless lives & communities shattered
The time for a comprehensive policy and research response is now!
Details in our review here www.nature.com/articles/s41...